LigaChem Biosciences
Overview
A publicly-traded, clinical-stage biopharmaceutical company that specializes in the discovery and development of medicines, with a focus on its proprietary antibody-drug conjugate (ADC) platform technology. The company was founded in 2006 and changed its name from LegoChem Biosciences in April 2024.
Portfolio Companies
3
Website
ligachembio.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Iksuda Therapeutics | Jun 2025 | Strategic | Lead |
| S-Alpha Therapeutics | Nov 2020 | Seed | Co-investor |
| 1ST Biotherapeutics, Inc. | Jan 2026 | Series D | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is LigaChem Biosciences based?
LigaChem Biosciences is headquartered in Daejeon, Daejeon, South Korea.
When was LigaChem Biosciences founded?
Founding year information for LigaChem Biosciences is not publicly available.
How many portfolio companies does LigaChem Biosciences have?
LigaChem Biosciences has 3 portfolio companies in Caplight's dataset.
What are some companies in LigaChem Biosciences's portfolio?
Portfolio companies visible on Caplight include Iksuda Therapeutics, S-Alpha Therapeutics, 1ST Biotherapeutics, Inc..
What was LigaChem Biosciences's most recent investment shown here?
LigaChem Biosciences's most recent investment in this portfolio sample was in 1ST Biotherapeutics, Inc. in 2026.
What sectors does LigaChem Biosciences focus on?
LigaChem Biosciences focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does LigaChem Biosciences focus on?
Stage focus information for LigaChem Biosciences is not publicly available.